Translational Relevance
Understanding the molecular mechanisms underlying head and neck cancer is essential to successfully developing novel avenues for targeted therapy. MicroRNAs play a powerful role in cancer biology, but identifying their gene specific targets is challenging given they can target numerous genes and pathways. MicroRNA specific roles and targets in head and neck cancer are largely unknown and to date no specific gene targets have been identified. By utilizing a novel integrative discovery approach, Clusterin and more specifically the unique transcript variant CLU-1, was identified as a specific miRNA-21 gene target with functional significance. By understanding the function and molecular mechanism of miRNA-21 and its specific gene targets, targeted therapy may have therapeutic potential. 
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. Over 48,000 new cases of HNSCC are diagnosed in the United States annually.
The 5-year overall survival remains around 50% partly due to advanced disease stage at diagnosis and the relatively high local and regional recurrence rates (1, 2) . The development of reliable biomarkers and more effective therapeutic agents are necessary to improve patient outcomes.
A major advance in cancer biology in the last decade is the discovery of small regulatory noncoding RNAs including microRNA (miRNA). A single miRNA may regulate the expression of many genes, and it has been proposed that over one third of all protein-coding genes are under translational control by miRNA (3) . These specific gene targets of miRNA are thought to be involved in cellular processes including differentiation, apoptosis, and proliferation, and seem to play an important role in a variety of human diseases including cancer (4) . Expression profiles of miRNA can be established and seem to be unique for various types of cancers (5) .
In this study, we verify that miRNA-21 is overexpressed in HNSCC and has protooncogenic properties through the regulation of Clusterin (CLU). Though no miRNA-21 specific targets have been found in HNSCC to date, several recent reports identified miRNA-21 alterations in primary HNSCC tissue samples (6) (7) (8) (9) . CLU only recently has been Author Manuscript Published OnlineFirst on December 10, 2013; DOI: 10.1158/1078-0432.CCR- associated with cancer promotion and metastasis (10) (11) (12) . CLU is considered as an enigmatic molecule because of the difficulties in the definition of its precise function. The role of CLU in carcinogenesis is unclear, with evidence that CLU has either a proapoptotic or a prosurvival role (11, (13) (14) (15) . It is now clear that CLU encodes at least two major mRNA variants, but still very little is known about their biological relevance and regulation (16).
Expression pattern of CLU and its transcript variants is unknown in HNSCC and normal tissues.
The aims of this study were: 1) to profile the miRNA expression in HNSCC, 2) to identify miRNA-21 targets that play a crucial role in HNSCC using an integrative microarray and bioinformatics techniques, and 3) to reveal the function of CLU and its regulation in HNSCC by a variant specific approach.
Materials and Methods

Human tissue samples
All human HNSCC tissue samples and normal mucosal tissues were obtained and used according to the policies of the JHMI institutional review board. Surgical specimens were obtained from surgical patients at John Hopkins Hospital. All specimens were quick-frozen in liquid nitrogen and stored at −80 °C. Microdissection of frozen tumor tissue was performed by a head an neck pathologist to assure HNSCC tumor yield of greater than 80%.
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Cell lines and culturing conditions
Normal oral keratinocyte -spontaneously immortalized cell line (NOK-SI) was developed by National Institute of Dental and Craniofacial Research collaborators at the National Institutes of Health as previously described (17). Nok-SI cells were grown in keratinocyte serum-free medium supplemented with bovine pituitary extract, and epidermal growth factor, and 1% Penicillin-Streptomycin. The HNSCC cell lines FaDu and SCC9 were expanded and passaged in DMEM/F12 medium supplemented with 10% FBS, 1% penicillin-streptomycin and Hydrocortisone (0.4 ug/ml). JHU-O28 HNSCC cell line was expanded and passaged in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin. All media 
miRNA array
Northern blots were performed to assure that the quality of RNA was adequate. RNA integrity was evaluated using denaturing gels and detection of the 18S and 28S rRNA bands.
This assured that the RNA lacked DNA contamination and that the RNA was not degraded, both of which could confound the array results. A custom-manufactured Affymetrix GeneChip ® from Asuragen (DiscovArray) was designed to miRNA probes derived from Sanger mirBase v9.2 database and published reports (18, 19) . Antigenomic probe sequences were provided by Affymetrix and derived from a larger set of controls used on the Affymetrix human exon array for estimating background signal, as described below. Other non-miRNA control probes were designed to have no sequence homology to the human genome and were used for spike-in external reference controls. The 3' ends of the RNA molecules were labeled with biotin using the mirVana™ miRNA Labeling Kit (Life Technology, Austin, TX). The Kit's dNTP mixture in the tailing reaction was replaced with a nucleotide mixture containing biotin-modified nucleotides (PerkinElmer, Waltham, MA).
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Hybridization, washing, staining, imaging, and signal extraction were performed according to Affymetrix protocols. Briefly, 100 ng of total RNA was labeled and hybridized to the microarray with ~13,000 probes including 600 known miRNA as well as putative miRNAs.
miRNA array data analysis
The signal processing implemented for the custom miRNA chip (DiscovArray) is a multi-step process involving probe-specific signal detection calls, background estimate and correction, constant variance stabilization (20) and either array scaling or global normalization. For each probe, an estimated background value was subtracted that is derived from the median signal of a set of GC content-matched anti-genomic controls. Arrays within a specific analysis experiment were normalized together according to the variance stabilization normalization (VSN) method described by Huber et al. Detection calls were based on a Wilcoxon rank-sum test of the miRNA probe signal compared to the distribution of signals from GC-content matched anti-genomic probes. Comparison between tumor and normal was tested with a two sample t-test with assumption of equal variance. One-way ANOVA was used for experimental designs with more than two experimental groupings (normal vs. tumor). These tests defined which probes were considered to be significantly differentially expressed, or "significant", based on a default p-value of less than 0.05 and at least 2-fold-change (log 2 qPCR for miRNA was performed as described previously (7) . The expression was normalized to U47 expression. The expression level was again determined by the DDCt method (21) . The average miRNA-21 expression level in normal versus tumor tissue was determined using the Mann Whitney U-test.
mRNA microarray
Total RNA extraction from HNSCC and normal mucosal human tissue samples and NOK-SI cells were performed using Trizol reagent, as above. RNA was further purified using the RNeasy Kit (Qiagen, Valencia, CA). Northern blots were performed to assure that the quality of RNA was adequate. RNA integrity was evaluated on a denaturing gel, and evaluating the presence of 18S and 28S rRNA. mRNA microarray analysis was carried out using the Affymatrix U133 Plus 2.0 array platform, both for the primary tissue and the NOK-SI cell line experiments samples. Significance analysis of microarrays (SAM) was performed to determine differential mRNA expression. A q-value or FDR was set at 5% to determine significant genes.
Quantification of CLU expression by RT-qPCR
Applied Biosystems gene expression kit Hs00971651_m1 specific for CLU was used for qPCR studies. The expression was normalized to 18s expression, using the Applied Biosystems gene expression kit Hs99999901_s1. The expression level was again determined by the DDCt method (21) . The CLU expression level in normal versus tumor tissue was determined using the Mann Whitney U-test.
Absolute quantification of CLU differential transcript expression by RT-qPCR
In order to further elucidate the baseline specific expression pattern of CLU in NOK-SI cell line, CLU transcript variant 1 (CLU-1) and CLU transcript variant 2 (CLU-2) specific primers were used to quantify the absolute expression ratio of each variant. Variant specific primer sequences were as follows (22) (reverse). Purified PCR products were synthesized using CLU-1 and CLU-2 specific primers.
Using standard curves based on the diluted purified PCR products, the input copy number of each transcript was determined by SYBR Green (Applied Biosystems) qRT-PCR.
Luciferase reporter assay
At 48 hours after transfection of miRNA-21 and the luciferase plasmids into NOK-SI cells, luciferase assays were performed using the dual-luciferase reporter assay system (Promega, 
the luminometer (Monolight 3020; BD Biosciences). Each Renilla luminescence value was first normalized to the control Firefly luciferase assay value contained in each luciferase construct. Each value is a mean of three separate transfections measured in triplicate.
Results
Identification of upregulated miRNAs in HNSCC
miRNA expression profiles of HNSCC were investigated using a miRNA microarray platform. Profiles from tumor samples (n=10) and non-tumor tissues (n=10) were compared (Supplementary Table 4 ). Thirty-two differentially expressed miRNAs were identified by miRNA array (Supplementary Table 5 ). To validate the microarray data, expression profiles of these miRNAs were analyzed by RT-qPCR in the same cohort of clinical samples that was used in miRNA array. Twenty-one significantly upregulated miRNAs were identified (Supplementary Table 6 ). miRNA-21, miRNA-155, and miRNA-375 have been previously reported as differentially expressed in HNSCC, but no specific gene targets of these miRNAs have been reported as of yet in HNSCC tumors (7, 8) . 
tumor types. miRNA-21 has been implicated in tumor growth, carcinogenesis, and response to chemotherapy in different malignancies (7, (23) (24) (25) (26) (27) (28) (29) Table 10 ).
In vivo studies included evaluation of the mRNA expression differences between normal mucosal and HNSCC tumor tissues. The Affymetrix U133 Plus 2.0 array platform was again used to evaluate differential mRNA expression in an independent tissue bank cohort that was separate from the primary tissue used in the miRNA discovery array. Analysis of the Combining these three approaches generated a candidate gene list (Table 1) Figure 2b ). miRNA-21 specificity for the CLU 3'UTR was lost when a short segment containing the miRNA-21 seed sequence was deleted from within the CLU 3'UTR region of the same luciferase reporter construct (Supplemental Figure 4) .
Variant specific analysis of CLU expression
There are two main variants in CLU (16), and both of them have a common 3' UTR sequence. Figure 5) .
Impact of CLU-1 on cell growth
The goal of this study was to identify key biologically active gene targets of miRNA-21 in HNSCC. miRNA-21 is overexpressed in HNSCC primary tissue and has proto-oncogenic activity in vitro (7) . Biologically significant targets should therefore in the least induce growth suppression when actively expressed. Growth effects of CLU-1 were then evaluated in vitro. CLU-1 was transiently overexpressed in NOKSI cell line to help clarify its potential effects on cell proliferation and results obtained using absorbance readings at regular 24 hour time point increments (Figure 4) . Overexpression of CLU-1 was confirmed by RT-qPCR (Supplementary Figure 6) . Table 3 ). CLU was significantly downregulated in primary HNSCC compared with normal mucosa tissue (P=0.0006, Figure   5a ). On the other hand, as shown in Supplementary Figure 1 (27, 36) . So these results suggest that CLU is an important target of oncogenic miRNA-21 in HNSCC, and miRNA-21 might be a key regulator of CLU in HNSCC.
The accumulated evidence indicates that CLU has many biological functions and plays an important role in cancer biology (37, 38) . Now it is generally accepted that there are two alternative isoforms of CLU protein; the secreted CLU (sCLU) and the nuclear form of CLU (nCLU). The existence of sCLU and nCLU might explain the contradictory role of CLU. sCLU is usually reported as a survival factor, on the other hand, nCLU is considered as proapoptotic associated with cell death (13, (39) (40) (41) (42) . During the last decade, many studies have discussed the complexity of CLU, but there is still a lack of precise information about the complex regulation of its expression, so CLU has been defined as an enigmatic protein. We identified CLU-1 as the dominant variant expressed in HNSCC that is regulated by miRNA-21. Our results also suggest that nCLU might originate at least partially from CLU-1 because forced expression of CLU-1 resulted in growth inhibition. It is now clear that CLU encodes more than one mRNA, but it still remains unclear how the protein isoforms are produced from the CLU gene and how each transcript relates to the diverse CLU isforms (46) . Furthermore, it is important to note that none of studies have isolated and sequenced the intracellular CLU (46) , so it is difficult to make a definitive conclusion regarding the origin of nCLU.
Several oncogenes including H-Ras, cMyc, and N-Myc -generally downregulate CLU (47) (48) (49) , so it is hypothesized that suppression of CLU by oncogenes is required for oncogenedependent transformation (46) . Our finding supports this hypothesis because miRNA-21 is an oncogenic microRNA. It is still hard to reveal the complexity of CLU regulation, but variant specific analysis of CLU at the transcriptional level may provide clues to understanding the complexity of CLU. However, further studies are necessary to reveal the mechanism for tissue-specific regulation of CLU.
Novel miRNA targets can be identified and validated utilizing a combined microarray analysis and bioinformatics target prediction methods. miRNA-21 is one of the crucial 
